Wire · operational-macro
Gossamer secures up to USD 250m to fund seralutinib through uncertain FDA path
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Gossamer Bio secured up to $250 million in structured financing to support the FDA approval process for seralutinib in pulmonary arterial hypertension, extending its cash runway into 2028 amid an uncertain regulatory path. The funding hinges on milestones including FDA acceptance of the new drug application expected in September 2026, with a potential regulatory decision in Q3 2027.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You now have a window to pursue or reassess contiguous regulatory opportunities as funding tied to seralutinib’s FDA acceptance shifts financial risk onto milestone delivery. Preparing for a potential cash crunch or partnership pivot before Q3 2027 could safeguard your runway and competitive stance.
◆ Coverage
1 source · 21 Aug 2026
◆ Related on Wire
◆ Topics